Loss of IFNγ receptor is an independent prognostic factor in ovarian cancer

Clinical Cancer Research

Volumn 13, Issue 14, 2007, Pages 4139-4145

  Duncan, Timothy J ^a   Rolland, Phil ^a   Deen, Suha ^b   Scott, Ian V ^c   Liu, David T Y ^b   Spendlove, Ian ^a   Durrant, Lindy G ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^c DERBY CITY GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON RECEPTOR;

ADULT; ARTICLE; CANCER SURVIVAL; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OVARY CANCER; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; TISSUE MICROARRAY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; PROGNOSIS; RECEPTORS, INTERFERON; SURVIVAL ANALYSIS;

EID: 34547095489     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2833     Document Type: Article

References (29)

1. Quinn M. Cancer Trends in England and Wales, 1950-1999. London: Office for National Statistics; 2001.
2. Bookman MA. Biological therapy of ovarian cancer: current directions. Semin Oncol 1998;25:381-96.
3. Hwu P, Freedman RS. The immunotherapy of patients with ovarian cancer. J Immunother 2002;25:189-201.
4. Kirby TO, Huh W, Alvarez R. Immunotherapy of ovarian cancer. Expert Opin Biol Ther 2002;2:409-17.
5. Rubin SC, Randall TC, Armstrong KA, Chi DS, Hoskins WJ. Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings. Obstet Gynecol 1999;93:21-4.
6. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004;22:329-60.
7. Madjd Z, Spendlove I, Pinder SE, Ellis IO, Durrant LG. Total loss of MHC class I is an independent indicator of good prognosis in breast cancer. Int J Cancer 2005;117:248-55.
8. Watson NF, Ramage JM, Madjd Z, et al. Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis. Int J Cancer 2006;118:6-10.
9. Ikeda H, Old LJ, Schreiber RD. The roles of IFN γ in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev 2002;13:95-109.
10. Burke F, Smith PD, Crompton MR, Upton C, Balkwill FR. Cytotoxic response of ovarian cancer cell lines to IFN-γ is associated with sustained induction of IRF-1 and p21 mRNA. Br J Cancer 1999;80:1236-44.
11. Marth C, Helmberg M, Mayer I, Fuith LC, Daxenbichler G, Dapunt O. Effects of biological response modifiers on ovarian carcinoma cell lines. Anticancer Res 1989;9:461-7.
12. Marth C, Muller-Holzner E, Greiter E, et al. γ-Interferon reduces expression of the protooncogene c-erbB-2 in human ovarian carcinoma cells. Cancer Res1990;50:7037-41.
13. Sers C, Husmann K, Nazarenko I, et al. The class II tumour suppressor gene H-REV107-1is a target of interferon-regulatory factor-1 and is involved in IFNγ-induced cell death in human ovarian carcinoma cells. Oncogene 2002;21:2829-39.
14. Meng RD, El-Deiry WS. p53-independent upregulation of KILLER/DR5 TRAIL receptor expression by glucocorticoids and interferon-γ. Exp Cell Res 2001;262:154-69.
15. Marth C, Fiegl H, Zeimet AG, et al. Interferon-γ expression is an independent prognostic factor in ovarian cancer. Am J Obstet Gynecol 2004;191:1598-605.
16. Nehme A, Julia AM, Jozan S, Chevreau C, Bugat R, Canal P. Modulation of cisplatin cytotoxicity by human recombinant interferon-γ in human ovarian cancer cell lines. Eur J Cancer 1994;30A:520-5.
17. Marth C, Windbichler GH, Hausmaninger H, et al. Interferon-γ in combination with carboplatin and paclitaxel as a safe and effective first-line treatment option for advanced ovarian cancer: results of a phase I/II study. Int J Gynecol Cancer 2006;16:1522-8.
18. Windbichler GH, Hausmaninger H, Stummvoll W, et al. Interferon-γ in the first-line therapy of ovarian cancer: a randomized phase III trial. Br J Cancer 2000;82:1138-44.
19. Kaplan DH, Shankaran V, Dighe AS, et al. Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 1998;95:7556-61.
20. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-7.
21. Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest 2000;80:1943-9.
22. Torhorst J, Bucher C, Kononen J, et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 2001;159:2249-56.
23. Dighe AS, Richards E, Old LJ, Schreiber RD. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN γ receptors. Immunity 1994;1:447-56.
24. Gao Y, Yang W, Pan M, et al. γδ T cells provide an early source of interferon γ in tumor immunity. J Exp Med 2003;198:433-42.
25. Bali A, O'Brien PM, Edwards LS, Sutherland RL, Hacker NF, Henshall SM. Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer. Clin Cancer Res 2004;10:5168-77.
26. Barton C, Davies D, Balkwill F, Burke F. Involvement of both intrinsic and extrinsic pathways in IFN-γ-induced apoptosis that are enhanced with cisplatin. Eur J Cancer 2005;41:1474-86.
27. Ossina NK, Cannas A, Powers VC, et al. Interferon-γ modulates a p53-independent apoptotic pathway and apoptosis-related gene expression. J Biol Chem 1997;272:16351-7.
28. Wall L, Burke F, Barton C, Smyth J, Balkwill F. IFN-γ induces apoptosis in ovarian cancer cells in vivo and in vitro. Clin Cancer Res 2003;9:2487-96.
29. InterMune. InterMune discontinues ovarian cancer trial: Intermune; Feburary 2006.